Navigation Links
Graffinity Enters into Drug Discovery Research Collaboration with Genentech
Date:10/15/2009

Heidelberg, Germany, October 15, 2009 / b3c newswire / - Graffinity Pharmaceuticals GmbH announced today that it has entered into a drug discovery research collaboration with Genentech, Inc, a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). With this collaboration Genentech will gain access to Graffinitys proprietary, fragment-based drug discovery technology.

Under the terms of the agreement, Graffinity will receive technology access fees and optional payments for follow-up chemistry for the generation of novel, small molecule hits against a number of drug targets. Financial details of the transaction were not disclosed.

Mathias Woker, Chief Business Officer of Graffinity, stated, We are very pleased that Genentech has decided to partner with us in fragment-based drug discovery. This marks our second collaboration with Genentech, and we think that this new agreement demonstrates how attractive Graffinitys very large fragment library and rapid surface plasmon resonance (SPR) screening technology are.

Kristina Schmidt, CEO of Graffinity, remarked, Our label-free, biophysics-based screening technology has shown to be an important element for companies which choose to work with us. With the help of this technology we enable partners, such as Genentech, to explore drug targets that would remain white spaces on the map of drug discovery, if researchers were limited to other conventional high-throughput screening techniques.


About Graffinity Pharmaceuticals GmbH - www.graffinity.com

Heidelberg, Germany based Graffinity Pharmaceuticals is a leader in the field of small molecule fragment based drug discovery. The company pursues high-profile drug discovery collaborations with leading pharmaceutical and biotechnology companies worldwide. Graffinity employs a flexible business model which allows it to tailor programs to the specific needs of each partner and offers numerous benefits to its customers on a straightforward fee-for-service basis. Graffinitys fragment screening platform combines chemical microarrays with a proprietary method for the standardized, label-free detection of compound-protein interactions via SPR imaging. The companys rapid and scalable drug discovery technology explores a rich chemical universe to identify drug fragments which address challenging drug targets. With its 110,000-compound library that contains 23,000 true fragments, Graffinity possesses one of the most diverse fragment libraries. During the past three years Graffinity has established collaborations with pharmaceutical and biotechnology partners including Amgen, AstraZeneca, Boehringer-Ingelheim, Elan, Pfizer and Rigel.
Graffinitys unique fragment based discovery platform was invented in 1998, and has been in routine industrial use since 2002 in screening more than 85 drug targets.

Graffinity Media Contact for Europe:

Dr. Kristina Schmidt
CEO
Graffinity Pharmaceuticals GmbH
Tel. +49 6221 6510-112
kristina.schmidt@graffinity.com

Graffinity Media Contact for the Americas and Asia:

Mathias Woker
CBO
Graffinity Pharmaceuticals GmbH
Tel. +1 (401) 301-1086
mathias.woker@graffinity.com


'/>"/>
b3c newswire

Related biology news :

1. NIH expands Human Microbiome Project; funds sequencing centers and disease projects
2. BIO-key(R) Enters Strategic Partnership With Nlets
3. BIO-key(R) Enters Strategic Partnership With Nlets
4. The first DFG research centers to be funded for another four years
5. Tellme Enters Automotive Market
6. From sheet metal elements to host cells: DFG launches 10 new collaborative research centers
7. Sicilian word enters British genetic language
8. NSF and EPA establish 2 centers for environmental implications of nanotechnology
9. Zebra Technologies Enters Into Revolving Credit Agreement to Support Company Growth
10. Weight Watchers vs. fitness centers
11. AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... --Technology Enhancements Accelerate Growth of X-ray Imaging This ... computed radiography markets in Thailand , ... (TIM). It provides an in-depth analysis of ... regional market drivers and restraints. The study offers revenue ... attractiveness, both for digital and computed radiography. Market participants ...
(Date:2/1/2016)... , Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces ... personality, Joey Fatone . Las Vegas , ... --> Las Vegas , where Joey appeared ... The new video ad was filmed at the Consumer Electronics Show ... the Wocket booth to meet and greet fans. ...
(Date:1/22/2016)... DUBLIN , January 22, 2016 ... has announced the addition of the  ... to their offering. --> ... of the  "Global Behavioral Biometric Market ... --> Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... , February 8, 2016 ... Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics ... Mark its Chlamydia trachomatis (CT) test to be launched on ... IVD Directive (98/79/EC), the CT test is now cleared for ... --> The launch of the io® CT test ...
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 ... the region,s trusted information source for community, health and ... San Diego) will integrate to enhance care coordination ... people to the services they need and to better ... to improve care.   San Diego ...
(Date:2/4/2016)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the leader ... Lanphier , Sangamo,s president and chief executive officer, will ... Therapeutic ® development programs and an overview of ... Thursday, February 11, 2016, at the Leerink Partners 5 ... being held in New York . ...
(Date:2/4/2016)... and MENLO PARK, Calif. , Feb. 4, ... and the "Company"), a biopharmaceutical company focused on the development ... will present at the 18 th Annual BIO ... at 10:00 a.m. EST in New York, NY ... and CEO, will provide an update on the ongoing clinical ...
Breaking Biology Technology: